Does TADALAFIL Cause Basal cell carcinoma? 92 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 92 reports of Basal cell carcinoma have been filed in association with TADALAFIL (Esokalli Testosterone Booster Oral Dissolving Film). This represents 0.3% of all adverse event reports for TADALAFIL.
92
Reports of Basal cell carcinoma with TADALAFIL
0.3%
of all TADALAFIL reports
6
Deaths
12
Hospitalizations
How Dangerous Is Basal cell carcinoma From TADALAFIL?
Of the 92 reports, 6 (6.5%) resulted in death, 12 (13.0%) required hospitalization.
Is Basal cell carcinoma Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TADALAFIL. However, 92 reports have been filed with the FAERS database.
What Other Side Effects Does TADALAFIL Cause?
Headache (3,196)
Drug ineffective (2,943)
Dyspnoea (2,881)
Death (1,917)
Diarrhoea (1,667)
Dizziness (1,374)
Nausea (1,368)
Asthenia (1,230)
Fatigue (1,135)
Hypertension (1,044)
What Other Drugs Cause Basal cell carcinoma?
ADALIMUMAB (1,547)
INFLIXIMAB (1,340)
METHOTREXATE (1,268)
RITUXIMAB (1,085)
ETANERCEPT (998)
ABATACEPT (852)
TOCILIZUMAB (761)
LENALIDOMIDE (685)
HYDROXYCHLOROQUINE (662)
LEFLUNOMIDE (657)
Which TADALAFIL Alternatives Have Lower Basal cell carcinoma Risk?
TADALAFIL vs TAFAMIDIS
TADALAFIL vs TAFAMIDIS MEGLUMINE
TADALAFIL vs TAFASITAMAB
TADALAFIL vs TAFASITAMAB-CXIX
TADALAFIL vs TAFINLAR